| 1 |
34463890 | Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. | 2022 Feb |
3 |
| 2 |
34656899 | Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. | 2022 Jan 5 |
1 |
| 3 |
34954595 | Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. | 2022 Feb 5 |
2 |
| 4 |
35172577 | Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and in Vitro Validation in Drug Resistant Chronic Myeloid Leukemia Cells. | 2022 Feb 28 |
1 |
| 5 |
33079733 | Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. | 2021 Jan 1 |
1 |
| 6 |
33420926 | HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs. | 2021 Sep |
2 |
| 7 |
33644598 | Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Biological Evaluation. | 2021 Feb 23 |
1 |
| 8 |
34043359 | Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. | 2021 Jun 10 |
1 |
| 9 |
34081246 | Treatment with Histone Deacetylase Inhibitor Attenuates Peripheral Inflammation-Induced Cognitive Dysfunction and Microglial Activation: The Effect of SAHA as a Peripheral HDAC Inhibitor. | 2021 Sep |
1 |
| 10 |
34884505 | Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices. | 2021 Nov 24 |
3 |
| 11 |
30332940 | Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. | 2020 |
1 |
| 12 |
31476841 | A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells. | 2020 Mar 1 |
1 |
| 13 |
32264925 | HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B- and T-cell lines. | 2020 Apr 7 |
1 |
| 14 |
32315286 | HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. | 2020 Jul 1 |
2 |
| 15 |
32359032 | Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. | 2020 May |
2 |
| 16 |
32760715 | Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. | 2020 |
4 |
| 17 |
32874829 | Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity. | 2020 Jul |
1 |
| 18 |
33189849 | Anticancer properties of chimeric HDAC and kinase inhibitors. | 2020 Nov 12 |
1 |
| 19 |
30348636 | Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. | 2019 Jan 15 |
1 |
| 20 |
30765872 | Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α. | 2019 Mar |
1 |
| 21 |
30767757 | Targeting Chromatin Remodeling for Cancer Therapy. | 2019 |
2 |
| 22 |
31126919 | Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P, Grant S. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010;115(22):4478-4487. | 2019 Jul 4 |
1 |
| 23 |
31186678 | BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3β activation. | 2019 Jun |
1 |
| 24 |
31206526 | Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells. | 2019 |
1 |
| 25 |
31267876 | Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents. | 2019 |
3 |
| 26 |
31311163 | Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities. | 2019 Jul 15 |
1 |
| 27 |
31456359 | Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. | 2019 Oct |
1 |
| 28 |
31531206 | Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE. | 2019 Sep 12 |
2 |
| 29 |
29393896 | Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition. | 2018 Feb 2 |
7 |
| 30 |
29945795 | Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). | 2018 Aug 15 |
1 |
| 31 |
30012171 | PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. | 2018 Jul 16 |
1 |
| 32 |
30121389 | Upregulation of Znf179 acetylation by SAHA protects cells against oxidative stress. | 2018 Oct |
3 |
| 33 |
30197679 | Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells. | 2018 Oct |
6 |
| 34 |
30243158 | Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. | 2018 Oct 5 |
3 |
| 35 |
30310596 | Silyl-mediated photoredox-catalyzed Giese reaction: addition of non-activated alkyl bromides. | 2018 Aug 28 |
1 |
| 36 |
30323893 | Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/IGH and BCL6/IGH gene arrangements and potential molecular targeted therapies. | 2018 Sep 11 |
1 |
| 37 |
30377559 | Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. | 2018 |
1 |
| 38 |
30385631 | Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. | 2018 Nov 20 |
1 |
| 39 |
27029827 | Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region. | 2017 |
3 |
| 40 |
27830268 | Butyrate alters expression of cytochrome P450 1A1 and metabolism of benzo[a]pyrene via its histone deacetylase activity in colon epithelial cell models. | 2017 May |
1 |
| 41 |
28222071 | Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. | 2017 Mar 28 |
2 |
| 42 |
28506198 | Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). | 2017 Jul 3 |
2 |
| 43 |
28526298 | Regulation of the Glycerol Transporter, Aquaporin-3, by Histone Deacetylase-3 and p53 in Keratinocytes. | 2017 Sep |
1 |
| 44 |
28535287 | A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I. | 2017 Aug 15 |
1 |
| 45 |
28648461 | The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. | 2017 Aug 1 |
6 |
| 46 |
28714868 | Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. | 2017 Aug 1 |
3 |
| 47 |
28953386 | Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. | 2017 Oct 26 |
4 |
| 48 |
28966246 | Synergistic Inhibition of Breast Cancer Cell Growth by an Epigenome-Targeting Drug and a Tyrosine Kinase Inhibitor. | 2017 |
1 |
| 49 |
28972015 | Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. | 2017 Nov 9 |
1 |
| 50 |
28988277 | A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. | 2017 Nov |
4 |